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Abstract: Cardiorespiratory fitness, as assessed through peak oxygen uptake (VO2peak), is a powerful
health indicator. We aimed to evaluate the influence of several candidate causal genetic variants
on VO2peak level in untrained Han Chinese people. A total of 1009 participants (566 women;
age [mean ± SD] 40 ± 14 years, VO2peak 29.9 ± 7.1 mL/kg/min) performed a maximal incremental
cycling test for VO2peak determination. Genomic DNA was extracted from peripheral whole blood,
and genotyping analysis was performed on 125 gene variants. Using age, sex, and body mass
as covariates, and setting a stringent threshold p-value of 0.0004, only one single nucleotide
polymorphism (SNP), located in the gene encoding angiotensin-converting enzyme (rs4295),
was associated with VO2peak (β = 0.87; p < 2.9× 10−4). Stepwise multiple regression analysis identified
a panel of three SNPs (rs4295 = 1.1%, angiotensin II receptor type 1 rs275652 = 0.6%, and myostatin
rs7570532 = 0.5%) that together accounted for 2.2% (p = 0.0007) of the interindividual variance in
VO2peak. Participants carrying six ‘favorable’ alleles had a higher VO2peak (32.3 ± 8.1 mL/kg/min)
than those carrying only one favorable allele (24.6 ± 5.2 mL/kg/min, p < 0.0001). In summary, VO2peak
at the pre-trained state is partly influenced by several polymorphic variations in candidate genes,
but they represent a minor portion of the variance.
Keywords: VO2max; maximal oxygen uptake; single nucleotide polymorphism; genomics; endurance
performance
1. Introduction
Cardiorespiratory fitness (CRF) is positively associated with endurance exercise performance [1]
and is a strong prognostic factor of morbidity and mortality from all causes and, particularly,
from cardiovascular disease (CVD) [2,3]. While both physical activity (PA) and exercise training can
modify CRF and are inversely associated with morbidity and mortality rates [4], CRF per se is a much
stronger predictor of prognosis in CVD and metabolic disorders [5,6]. The measure of an individual’s
peak capacity to perform dynamic aerobic exercise is dependent on the synergistic action of pulmonary,
cardiovascular and muscle tissue via a suite of physiological actions that effectively transport and
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deliver oxygen from the atmosphere to mitochondria in working muscles [7,8]. Accordingly, CRF can
be assessed by directly measuring the peak oxygen uptake (VO2peak) reached during a graded dynamic
exercise test until exhaustion, involving large muscle masses (e.g., running or bicycling), or by indirectly
estimating this variable from the peak workload achieved. Nevertheless, direct evaluation of VO2peak
is considered the gold standard measure of CRF and, indeed, the American Heart Association recently
advocated for the routine assessment of this measure as a clinical vital sign [9].
VO2peak is characterized by a high interindividual variability even in people of the same sex,
age and with the same level of PA and exercise training. This variability is believed to be related, at least
partly, to heredity. A seminal study by Claude Bouchard and colleagues found comparable VO2peak
values in brothers of the same sibship, and the similarities in VO2peak were even greater in dizygotic
and monozygotic twins [10]. The authors suggested that the genetic effect on VO2peak reached ~40%.
In a similar study of 170 individuals and their offspring (n = 259), it was found that about 50% of
the interindividual variance in VO2peak corresponded to heritable factors after adjusting for age, sex,
body mass, and body composition [11]. These findings have been replicated in subsequent studies with
siblings and twins [12] and, to date, it is commonly accepted that VO2peak is influenced by both genetic
(~50–60%) and environmental factors. It has also been reported that twins with similar VO2peak values
present with comparable levels of a variety of PA indices [13], suggesting that part of the heritability of
VO2peak in twins might be due to the similarity of their PA levels. In fact, in a recent analysis of 123,545
single nucleotide polymorphisms (SNPs), only nine were associated with VO2peak [14]. The authors of
this study found that those individuals whose genotype was associated with a high VO2peak value had
a lower CVD risk (e.g., less visceral fat or lower total blood cholesterol), but they did not calculate
the additive effect that the nine SNPs had on the interindividual variability of VO2peak. There is
therefore controversy on the influence of genetics on VO2peak, which mostly likely stems from the
discrepancies between studies conducted on siblings/twins vs those conducted on individuals with no
familial connection. In this regard, determining the actual genetic contribution to the interindividual
variability in VO2peak would be of major importance to inform how environmental factors—including
lifestyle—might contribute to heightened VO2peak values. It is possible that if the influence of genetics
on VO2peak is low, exercise training might be a determining factor to enhance ‘innate’ VO2peak even in
those less genetically predisposed, with obvious subsequent benefits for cardiovascular health. Indeed,
previous research has reported VO2peak increases of up to 44% after strenuous training interventions,
which would support a strong influence of environmental factors on CRF [15].
Aerobic/endurance exercise-based training appears to be the most effective way to augment
VO2peak. Exercise training increases rather than decreases the individual differences seen at baseline
VO2peak because the response to training itself shows large variation [16]. A genome-wide association
study based on 324,611 SNPs found that only 21 SNPs could explain 48.6% of the change in VO2peak
induced by a 20-week exercise training program [17]. Among them, rs6552828, located in the acyl-CoA
synthase long-chain member 1 (ACSL1) gene, accounted by itself for 6% of the training-induced
enhancement in VO2peak. In a recent meta-analysis of 35 articles on the genetic influence on VO2peak
trainability, a total of 97 genes were associated with this phenotype, although only 13 genetic variants
were reproduced by more than two investigations [18].
Knowledge on the genetic influence on baseline VO2peak (i.e., in isolation from training) is mainly
based on studies conducted on siblings/twins or in individuals of Caucasian descent, and it remains
to be determined whether the genetic variants that might be associated with baseline VO2peak are
similar or different in individuals of other ethnicities. Thus, the aim of the present study was to assess
the influence of several candidate genetic variants in the interindividual variation of baseline CRF
measured as VO2peak, in Han Chinese individuals.
Genes 2020, 11, 555 3 of 16
2. Materials and Methods
2.1. Participants
A total of 1047 participants (56% women) volunteered to participate in the study. The sample was
recruited from five cities in China: Beijing, Xi’an, Guangzhou, Shenyang, and Tianjin. Inclusion criteria
were the following: male/female aged 18–69 years; being of Chinese (Han) descent and unrelated to
the other participants; having no CVD, diabetes or abnormal glucose tolerance, or any other acute or
chronic disease; and being untrained (i.e., ≤ 2 sessions/week of ≤ 30min of regular physical exercise
in the previous 12 months). One week before the start of the investigation, participants were fully
informed of the experimental procedures and signed an informed written consent to participate in
the investigation. The study protocol was approved by the Institutional Review Board of the China
Institute of Sport Science.
2.2. Experimental Design
This is an observational cross-sectional study aimed at determining the genetic influence of target
genes on the interindividual variability in VO2peak values in untrained Han Chinese individuals.
We selected untrained individuals to avoid any influence of exercise training or planned PA in
the analysis.
2.3. Experimental Protocol
The day of the first experimental trial, participants underwent a medical examination (including
medical history and other routine physical examinations) carried out by a licensed physician, to ensure
the suitability of all participants to take part in the research protocols. On the same day, whole body
dual-energy X-ray absorptiometry (GE Lunar DPX system, Madison, WI, USA) assessments were
performed and used to calculate body fat and fat-free mass following previous recommendations [19].
VO2peak (in mL/kg/min) was determined during a continuous incremental exercise test to volitional
fatigue performed on a bicycle ergometer (Ergoselect 100, Ergoline GmbH, Bitz, Germany). Before
tests, participants were familiarized with the ergometer and with the rating of perceived exertion
(RPE), as measured by the Borg 6–20 scale [20]. Participants performed a standardized warm-up
(5 min cycling at 20 W and 60 rpm), and the workload (starting at 20 W) was then increased by 25 W
(men) or 20 W (women) every 2 minutes until volitional exhaustion. In participants >60 years of age,
the workload was increased by 20 W (men) or 15 W (women) every 2 minutes. During the test, gas
exchange data were measured ‘breath-by-breath’ with a metabolic cart (MetaMax 3B, Cortex Biophysik
GmbH, Leipzig, Germany). Certified calibration gases (16.0% O2, 5.0% CO2, Cortex Biophysik) and a
3-L syringe were used to calibrate the gas analyzer and the flow meter, respectively, before each test.
VO2peak was defined as the highest VO2 value (60-s average) obtained during the test. VO2peak was
considered valid when participants achieved at least two of the following criteria: (i) RPE >17, (ii) VO2
difference between the last two consecutive loads <0.15 L/min, (iii) respiratory exchange ratio >1.1,
and (iv) peak heart rate >85% of the age-adjusted estimate [21]. Heart rate was recorded with a chest
strap transmitter (Polar RS400, Polar Electro, Kempele, Finland). The environmental temperature was
similar in all measurement centers (~22 ◦C, 40% relative humidity).
On a different day during the week of testing, genomic DNA was extracted from peripheral
whole blood samples using the Wizard Genomic DNA Purification Kit (Promega; Madison, WI, USA).
Genotyping was performed at Shanghai Benegene Biotechnology, LTD (Shanghai, China). For analysis,
a list of 125 SNPs (Tables A1 and A2, Tables A3 and A4) for the Han population of Beijing, China (CHB)
was obtained from the International HapMap Project database. Haplotype-tag SNPs were selected
using the following criteria: minor allele frequency ≥0.01 and measure of linkage disequilibrium
(r2 > 0.8). Initially, genes associated with cardiovascular responses to exercise were chosen, and genes
associated with endurance performance, muscle performance, or body composition were then added
as all of these factors might contribute to the value of VO2peak (Table 1).
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Table 1. Target genes selected for the investigation.
Gene Numbers of SNPs Chromosome Location References
ACE 3 chr17:58,908,166-58,928,711 [22]
ACE2 2 chrX:15,489,077-15,529,058 [23,24]
ACSL1 15 chr4: 185,911,544-185,986,209 [17,25]
ACTN3 1 chr11:66,313,866-66,330,800 [26,27]
AGT 13 chr1:228,902,892-228,918,564 [28,29]
AGTR1 9 chr3:149,898,348- 149,943,480 [30,31]
AGTR2 3 chrX:115,214,031-115,221,847 [32]
BDKRB2 28 chr14:95,738,950-95,782,536 [33]
FGF21 2 chr19:53,949,156-53,955,394 [34]
FGFR2 1 chr10:123,237,848-123,357,972 [34]
FNDC5 3 chr1:33,327,869-33,338,083 [35]
FST 3 chr5: 52,812,352-52,817,659 [36,37]
FTO 3 chr16:53,737,875-54,155,853 [38]
GDF8 4 chr2:190,920,423-190,927,455 [39,40]
IL-6 7 chr7:22,733,345-22,738,141 [41]
IL-15 2 chr4:142,557,752-142,665,140 [42,43]
ITLN1 5 chr1:160,846,329-160,854,960 [44]
PGC-1α 6 chr4: 23,756,664-23,905,712 [45]
PGC-1β 1 chr5:149,109,861-149,234,585 [45]
PPRC1 1 chr10: 103, 880, 777-103, 902, 078 [45]
PRDM16 2 chr1: 2,985,732-3,355,185 [46]
PYY 5 chr17:39,385,633-39,437,363 [47]
REN 5 chr1: 202,390,571-202,402,088 [48]
RETN 1 chr19:7,639,972-7,641,340 [49]
Abbreviations: SNP, single nucleotide polymorphism. Abbreviations for gene names: ACE, angiotensin-converting
enzyme; ACE2, angiotensin-converting enzyme 2; ACSL1, acyl-CoA synthase long-chain member 1; ACTN3,
alpha-actinin-3; AGT, angiotensinogen; AGTR1, angiotensin II receptor type 1; AGTR2, angiotensin II receptor type
2; BDKRB2, bradykinin receptor B2; FGF21, Fibroblast growth factor 21; FGFR2, fibroblast growth factor receptor 2;
FNDC5, fibronectin type III domain-containing protein 5; FST, follistatin; FTO, fat mass and obesity-associated protein
(also known as ‘alpha-ketoglutarate-dependent dioxygenase’; GDF8, growth differentiation factor 8 (also known as
‘myostatin’); IL-6, interleukin 6; IL-15, interleukin 15; ITLN1, intelectin 1; PGC-1α, peroxisome proliferator-activated
receptor-gamma coactivator (PGC)-1alpha; PGC-1β, peroxisome proliferator-activated receptor-gamma coactivator
(PGC)-1beta; peroxisome PPRC1, proliferator-activated receptor gamma, coactivator-related 1; PRDM16, PR domain
containing 16; PYY, peptide YY; REN, renin; RETN, resistin.
For high-throughput genotyping of SNPs, we used a matrix-assisted laser desorption/ionization
time-of-flight mass spectrometry (MALDI-TOF MS) platform (Agena, San Diego, CA, USA). Primers
for the polymerase chain reaction (PCR) and single-base extension were designed using the Assay
Designer software package (Assay Design Suite V2.0, Agena, San Diego, CA, USA). Genotyping was
performed as described elsewhere [50].
2.4. Statistical Analysis
All statistical analyses were performed using SAS 9.4 statistical package (SAS institute, Inc.,
Cary, NC, USA) and PLINK (v1.07). Hardy–Weinberg Equilibrium (HWE) was tested using χ2 tests.
Linear regression analyses were conducted to assess the association—expressed as standardized
regression coefficients (β)—between each SNP and VO2peak, with age, body mass and sex as covariates.
The Bonferroni correction for multiple comparisons was applied to test for statistically significant
associations between SNPs and VO2peak, thereby setting the minimum level of significance at p < 0.0004
(i.e., 0.05 divided by the number of SNPs, i.e., 125). A multivariable regression analysis was then
conducted to assess the overall contribution of the most significant SNPs to the interindividual
variability of VO2peak. All SNPs with p < 0.05 were included, and a regression model with backward
elimination was used to filter-out redundant SNPs. By using a threshold of 5.0 points in the variance
inflation factor, we avoided multicollinearity. SNPs that were retained in the final backward elimination
model were then analyzed with a multivariate regression model using forward selection. The produced
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regression equation was accepted at a significance level of p <0.01. The values of R2 were adjusted
for the number of cases and parameters in the analysis. The relative contribution (R2) of each SNP in
relation to the explained variance in VO2peak was calculated as follows (Equation (1)):
Partial contribution (R2 adjusted) = ([β for parameter] / Σ [of all β in equation]), (1)
In the SNPs retained in multiple regression, VO2peak values were compared among genotypes
by using one-way analysis of variance (ANOVA). When the ANOVA showed a significant F value,
pairwise differences were assessed using the Tukey post-hoc test. By using the SNPs retained in
multiple regression analyses, we calculated a weighted genotype score to assess the combined influence
of the SNPs on VO2peak following the procedure of Williams and Folland [51]. First, each genotype was
scored within each SNP by assigning 0 arbitrary units (a.u.) to homozygotes for the allele theoretically
associated with low VO2peak, 1 a.u. to heterozygotes, and 2 a.u. to homozygotes for the allele associated
with high VO2peak, following an additive model. Each SNP was then weighted by its β-coefficient
(allele effect) based on the assumption that all SNPs of interest have independent effects and contribute
in an additive manner to VO2peak. Finally, the scores obtained for each SNP were summed to obtain
a unique weighted genotype score for each participant (theoretical range: 0–6 a.u.). For clarity, we
merged data of participants by using intervals of 1 a.u. Differences in VO2peak between participants
in the different groups were assessed by one-way analysis of variance and using the least significant
difference post hoc test. Finally, the ability of weighted genotype score to distinguish individuals with
low or intermediate CRF (i.e., below or above 28 mL/kg/min, as proposed by Kodama et al. [52]) was
assessed using a receiver operating characteristic (ROC) curve and by determining the area under the
ROC curve (AUC).
3. Results
Of the initial 1047 individuals recruited, valid VO2peak measurements were obtained for 1009
individuals (566 women), and thus only these participants were included in the analyses. The main
characteristics of the participants are shown in Table 2.
Table 2. Main characteristics of the study participants (N = 1009) and their association with peak
oxygen uptake.
Variable Mean ± SD Range β p-Value
Age (year) 40 ± 14 19–69 −0.27 <0.001
Height (cm) 165.3 ± 8.3 146.2–187.0 0.31 <0.001
Body mass (kg) 64.3 ± 11.6 39–104 −0.01 0.523
Body mass index (kg/m2) 23.4 ± 3.1 15.6–34.8 −0.64 <0.001
Body fat (%) 27.1 ± 8.8 4.5–44.5 −0.58 <0.001
Fat-free mass (kg) 43.8 ± 9.5 24.8–70.1 0.31 <0.001
Genotyping was successful (i.e., successful determinations for all SNPs) in 1006 of 1009 participants
(99.7%). From the 125 SNPs analyzed, 10 were discarded because they deviated from HWE (Table A2),
10 because they had a MAF <5% (Table A3), and two because only one genotype was detected across
the group of participants (Table A4). From the remaining pool of 103 SNPs, only rs4295, located in the
angiotensin-converting enzyme (ACE) gene, was significantly associated with VO2peak (p < 2.9 × 10−4,
β = 0.87; minor allele (G) frequency, 38.1%, heterozygosity frequency, 47.4%).
Figure 1 shows the distribution of VO2peak values in the study sample. Approximately 2.5% of all
participants had a VO2peak <20 mL/kg/min and 1.4% had a VO2peak level >50 mL/kg/min.
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Individual VO2peak values for each genotype of the ACE rs4295, AGTR1 rs275652, and GDF8
rs7570532 polymorphisms are shown in Figure 3. The one-way ANOVA revealed statistically significant
differences in ACE rs4295 (F = 4.95, p = 0.007) and AGTR1 rs275652 (F = 3.90, p = 0.021) polymorphisms,
while the ANOVA did not show differences for GDF8 rs7570532 (F = 1.64, p = 0.194) polymorphism.
Specifically, GG homozygotes in ACE rs4295 had a mean VO2peak of 31.1 ± 7.9 mL/kg/min, which was
higher than that found in heterozygotes (GC, 29.8±6.9 mL/kg/min; p = 0.049) or in homozygotes for the
common allele (CC, 28.9 ± 6.7 mL/kg/min; p = 0.013). In addition, AA homozygotes in AGTR1 rs275652
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had a mean VO2peak of 30.0 ± 7.3 mL/kg/min, which was higher than that found in homozygotes for
the minor allele (CC, 25.5 ± 5.3 mL/kg/min; p = 0.024).
Table 3. List of single nucleotide polymorphisms associated with peak oxygen uptake in the study
participants. Model 1, with genetic-only influence; model 2 with covariates.
SNP Partial R2 p-Value
Model 1
ACE rs4295 0.0110 0.0024
AGTR1 rs275652 0.0056 0.0293
GDF8 rs7570532 0.0053 0.0342
Model 2
Age 0.2052 <0.0001
Sex 0.1800 <0.0001
Weight 0.0994 <0.0001
ACE rs4295 0.0063 0.0015
GDF8 rs7570532 0.0046 0.0058
BDKRB2 rs4144131 0.0037 0.0135
Abbreviation: SNP, single nucleotide polymorphism; Abbreviations for gene names: ACE, angiotensin-converting
enzyme; AGTR1, angiotensin II receptor type 1; BDKRB2, bradykinin receptor B2; GDF8, growth differentiation
factor 8 (also known as ‘myostatin’).
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Figure 3. Box-and-whisker plots showing peak oxygen uptake (VO2peak) in the study participants
according to genetic variations in the genes for angiotensin-converting enzyme (ACE; rs4295),
angiotensin II receptor type 1 (AGTR1; rs275652), and growth differentiation factor 8 (GDF8, also known
as ‘myostatin’; rs7570532). The lines in the box represent the first, second (median) and third quartiles,
and the whiskers represent 1.5 × interquartile ranges. Each dot represents one individual within the
specified genotype. (*) Depicts a statistically significant difference from CC genotype in ACE rs4295
polymorphism at p < 0.05. (†) Depicts a statistically significant difference from CC genotype in AGTR1
rs27565 polymorphism at p < 0.05.
A weighted genotype score was constructed using the three SNPs shown in model 1 of genetic-only
influence. Participa ts were categorized with a g notype scor from 0 a.u., indicating the presence of
homozygosity for all the alleles a sociated with a lower VO2peak in ACE ( s4295), AGTR1 (rs275652)
and GDF8 (rs7570532), to 6 a.u., indicating the presence of homozygosity for all the alleles associated
with a higher VO2peak in the aforementioned SNPs. A linear effect was found for genotype score on
VO2peak (Figure 4). Specifically, the individuals with 6 a.u. had a higher VO2peak than those with
scores up to 4.0 a.u. (p < 0.05). In addition, participants with scores >2 a.u. had a higher VO2peak than
those with scores <1.0 a.u. (p < 0.05). ROC analysis showed significant discriminatory accuracy of the
weighted genotype score in the identification of individuals with low/intermediate CRF (AUC = 0.542)
with a sensitivity of 0.733 and a specificity of 0.305.
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Figure 4. Peak oxygen uptake (VO2peak) levels in the study participants according to the genotype score
(computed by using a weighted score of angiotensin-converting enzyme rs4295, angiotensin II receptor
type 1 rs275652 and growth differentiation factor 8 rs7570532 genotypes). Abbreviations/symbols: a.u.,
arbitrary units; a, difference from 0–0.9 a.u. at p<0.05; b, difference from 1.0–1.9 a.u. at p < 0.05; c,
difference from 2.0–2.9 a.u. at p < 0.05; d, difference from 3.0–3.9 a.u. at p < 0.05.
4. Discussion
CRF, particularly when objectively determined as VO2peak, is strongly associated with endurance
performance and health outcomes. Indeed, VO2peak reflects the peak integrative ability of the organism
to deliver oxygen from the atmosph re to the mitochondria of working mu cles. The VO2peak is thus
determi ed, am ng oth r factors, by peak cardiac output and pulmonary ventilation, lung diffusion
capacity, blood and plasma volume, hemoglobin mass, and muscle capill ry density and oxidative
capacity [53]. Importantly, the mean values of VO2peak of our participants (29.9 ± 7.1 mL/kg/min r
8.5 metabolic equiv lents, i.e., METs) were bare y abov the min mum he lthy threshold for all-cause
and CVD mortality in middle-aged me /wom n (i.e., 8 MET [52]). It is thus of med al importance to
determine whether genetic fa tors (including specific gene variants) are associated w th variability
of CRF around (i.e., above vs below) the 8-MET cutoff. Previous research n siblings/twins suggests
that 50%–60% of the variance of VO2peak is associated with heredity [10,12]. These values seem
surprisingly h gh given the variety of physiologic l proce ses and body tissues involved in the upt ke
and utilization of oxygen in muscle mitochondria. Indeed, there is open deb about t e limits of the
evidence that support the elative influence of genetics on the variability and trainability of CRF [54,55].
Our findings question the high heritabilit of VO2peak, at least in Chinese individuals with no
familial connection. From the 125 SNPs selected for our study, only one (ACE rs4295) was as ociated
with VO2peak. Also, the best model obtained through multiple regression analyses could only explain
~2.2% of the interindividual variance in VO2peak. As in the study by Bye et al. [14], we created a
polygenic score to determine whether those individuals with a higher number of alleles associated
with VO2peak did indeed present with higher values of this parameter. The only differences found
between our findings and those of the Bye et al. study were the number of SNPs included in the
polygenic score (7 vs 3, respectively) and the use of an intermediate genotype score for heterozygotes,
which was not included by Bye et al. Interestingly, in both studies, participants with the theoretically
lowest (or ‘less favorable’) genotype scores had the lowest VO2peak (22–24 mL/kg/min), which was
significantly lower than for those with the theoretically highest (or ‘most favorable’) genotype score
(~32 mL/kg/min). These findings suggest that only a small number of SNPs are associated with the
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odds of having high VO2peak values in untrained individuals. The variance of the interindividual
variability in VO2peak explained with these genotypes is low and the addition of favorable alleles might
produce a change of 8–10 mL/kg/min. This genetic influence might be considerable in clinical terms
because each 1-MET (or 3.5 mL/kg/min) increase in CRF has been shown to confer a 12% improvement
in survival in Caucasian (North-American) men [6]. Moreover, as mentioned above, it is of clinical
importance to surpass the 8-MET threshold, and in fact, adults with a CRF clearly above this level
(>10 METs) have a remarkably reduced CVD risk [56]. In this regard, the probability of surpassing the
8-MET threshold (equivalent to 28 mL/kg/min) was doubled in those participants that carried the six
‘favorable’ alleles (Figure 4).
Only three SNPs were included in the final multiple regression model. ACE rs4295 has not been
previously associated with endurance performance, but it is located in the same linkage disequilibrium
block as the widely studied ACE insert(I)/deletion(D) polymorphism (rs4340) [57]. The ACE gene
encodes angiotensin-converting enzyme and the I allele might be associated with lower circulating
levels of enzyme, and the II genotype potentially associated with performance in endurance athletes
(odds ratio 1.35; 95% confidence interval, 1.17 to 1.55 [58]). However, several studies have found no
association between the ACE I/D genotype and VO2peak values in trained [59] and untrained [60,61]
individuals. With regard to the ACE rs4295 variation found in the present study, although its influence
on CRF needs to be replicated in other cohorts, our findings bolster the role of angiotensin-converting
enzyme and its coding gene as predictors of CRF-related phenotypes. We also found that carriage
of the C allele in the AGTR1 rs275652 polymorphism was negatively associated with VO2peak values.
This gene encodes the angiotensin II receptor 1 (AT1R), and polymorphisms in AGTR1 have been
suggested to be involved in the physiological response to hypoxia [62]. AT1R is broadly expressed in
different tissues and mediates most of the classical actions of angiotensin II, including vasoconstriction
and vascular smooth muscle cell proliferation [63]. Thus, under hypoxic conditions, angiotensin II
engages AT1R to modulate the pulmonary vasoconstrictive response [64]. Although speculative, it is
possible that the C allele in AGTR1 rs275652 might exacerbate pulmonary vasoconstriction during
exercise owing to a higher activation of AT1R for a given concentration of angiotensin II [65]. The last
SNP included in the model explaining VO2peak was rs7570532, a genetic variation in GDF8 encoding
myostatin. This and other SNPs in GDF8 have been indirectly associated with a major cardiometabolic
condition, obesity [39], but other authors have reported no association of rs7570532 with endurance
performance [40]. Myostatin controls the differentiation and proliferation of skeletal muscle throughout
embryonic development and regulates muscle growth during adulthood. Mutations in GDF8 that
produce non-functional myostatin result in the increased growth of skeletal muscle, demonstrating
the existence of a powerful mechanism to control muscle size in normal individuals through this
protein [66]. Based on these findings and given the positive association between muscle mass and
VO2peak [66–68], it is possible that GDF8 rs7570532 confers a small but significant predisposition to
higher VO2peak values. Further research on these three SNPs is clearly warranted.
We acknowledge that the current investigation has some limitations. First, our study sample
was heterogeneous in terms of age, sex, and anthropometric characteristics (Table 1). Although we
used these variables as covariates in linear regression analyses, the high variability of these variables
might have partially influenced our results. In fact, when they were included in multiple regression
analyses (Figure 2b), the explained variance of VO2peak increased up to 50.1%. Second, our study only
included participants of Han Chinese descent and the results might therefore not be applicable to
other ethnicities. Of note, the Han Chinese constitute the world’s largest ethnic group (constituting
~18% of the global population), but further studies in other large ethnic groups will be needed to
confirm/discard the generalizability of these results. Lastly, we only analyzed 125 SNPs and thus it is
plausible that other candidate genes might have an influence on VO2peak.
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5. Conclusions
The present study shows that in a cohort of untrained Han Chinese individuals, VO2peak is
influenced by a very few polymorphic variations in key genes even in isolation of training adaptations.
The genetic influence accounted for ~2.2% of the interindividual variance in VO2peak, at least with the
125 SNPs included in this investigation. Although more research is needed, these data suggest that
environment, probably more than genetics, is responsible for most of the interindividual variability in
VO2peak among healthy Han Chinese adults.
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Appendix A
Table A1. List of SNPs investigated for association with VO2peak (mL/kg/min) in Han Chinese
untrained individuals.
Gene SNP MA MAF
ACE rs4295 G 38.1
ACE rs4341 G 34.9
ACE rs4363 G 38.7
ACE2 rs6632677 C 9.2
ACSL1 rs10022018 G 24.4
ACSL1 rs11732302 C 24.7
ACSL1 rs12503643 G 45.9
ACSL1 rs12644905 T 19.6
ACSL1 rs13126272 T 11.0
ACSL1 rs1803898 A 7.3
ACSL1 rs2292898 C 7.8
ACSL1 rs13120078 A 8.2
ACSL1 rs2280297 C 47.6
ACSL1 rs2292899 A 38.1
ACSL1 rs3749233 A 25.9
ACSL1 rs3792312 G 41.7
ACSL1 rs4069938 G 37.7
ACSL1 rs6552828 G 35.2
ACSL1 rs902177 C 28.2
ACTN3 rs1815739 T 41.7
AGT rs10864770 T 34.5
AGT rs11568046 C 12.9
AGT rs2478523 C 46.0
AGT rs2478544 C 21.8
AGT rs2493132 T 37.3
AGT rs3789671 G 45.5
AGT rs3789678 T 18.7
AGT rs3889728 A 49.4
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Table A1. Cont.
Gene SNP MA MAF
AGT rs5050 G 14.8
AGT rs6687360 C 33.1
AGT rs699 T 19.7
AGT rs7079 A 16.2
AGT rs7536290 G 22.0
AGTR1 rs2131127 T 37.4
AGTR1 rs275652 C 13.6
AGTR1 rs3772616 A 17.8
AGTR1 rs385338 G 18.0
AGTR1 rs5182 C 28.1
AGTR1 rs6801836 C 14.2
BDKRB2 rs10130005 C 18.3
BDKRB2 rs10132462 T 28.1
BDKRB2 rs11160322 C 23.0
BDKRB2 rs11627176 G 12.0
BDKRB2 rs11627761 T 15.3
BDKRB2 rs11848502 T 30.1
BDKRB2 rs12433275 T 16.3
BDKRB2 rs12888402 C 16.7
BDKRB2 rs1799722 C 48.0
BDKRB2 rs1959053 T 25.3
BDKRB2 rs2069575 A 20.4
BDKRB2 rs2069578 G 39.1
BDKRB2 rs2069586 A 16.5
BDKRB2 rs2069588 T 18.0
BDKRB2 rs2369521 G 35.6
BDKRB2 rs4144131 A 43.9
BDKRB2 rs4900315 C 46.5
BDKRB2 rs4900318 A 49.7
BDKRB2 rs4905470 A 20.0
BDKRB2 rs4905474 A 37.1
BDKRB2 rs6575577 G 22.5
BDKRB2 rs7155797 T 44.4
BDKRB2 rs7161665 C 47.9
BDKRB2 rs8013400 T 28.5
BDKRB2 rs8016905 A 32.7
BDKRB2 rs885818 T 13.4
BDKRB2 rs945039 T 42.9
FGFR2 rs2071616 T 8.8
FNDC5 rs16835198 T 47.7
FNDC5 rs3480 G 24.8
FST rs3797296 G 17.3
FST rs3797297 T 12.8
FTO rs1421085 C 10.4
FTO rs1558902 A 10.6
FTO rs9939609 A 10.4
GDF-8 rs16832288 A 19.9
GDF-8 rs7570532 G 26.0
IL-15 rs1057972 A 49.9
IL-6 rs1524107 C 29.3
IL-6 rs2069840 G 7.3
IL-6 rs2069830 G 27.2
IL-6 rs2069837 G 20.1
IL-6 rs2069852 G 37.0
ITLN1 rs2274906 A 36.5
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Table A1. Cont.
Gene SNP MA MAF
ITLN1 rs2274910 T 29.6
ITLN1 rs2297560 T 13.9
ITLN1 rs6427552 C 24.7
PGC-1α rs12374310 C 43.9
PGC-1α rs12650562 C 49.5
PGC-1α rs251468 T 19.8
PGC-1α rs4452416 G 13.4
PGC-1α rs4697425 G 30.8
PGC-1α rs6821591 C 29.9
PRDM16 rs12409277 C 42.0
PRDM16 rs2236518 A 44.5
PYY rs10853114 C 37.8
PYY rs12953033 A 6.9
PYY rs162430 G 35.3
PYY rs1859223 G 27.2
REN rs11571078 T 12.7
REN rs1464816 T 24.4
REN rs2368564 T 20.3
REN rs4951313 G 29.1
REN rs5707 G 40.3
RETN rs3745367 A 35.5
Abbreviations: MA, minor allele; MAF, minor allele frequency; SNP, single nucleotide polymorphism; VO2peak, peak
oxygen uptake. Abbreviations for gene names: ACE, angiotensin-converting enzyme; ACE2, angiotensin-converting
enzyme 2; ACSL1, acyl-CoA synthase long-chain member 1; ACTN3, alpha-actinin-3; AGT, angiotensinogen;
AGTR1, angiotensin II receptor type 1; AGTR2, angiotensin II receptor type 2; BDKRB2, bradykinin receptor
B2; FGF21, Fibroblast growth factor 21; FGFR2, fibroblast growth factor receptor 2; FNDC5, fibronectin type
III domain-containing protein 5; FST, follistatin; FTO, fat mass and obesity-associated protein (also known as
‘alpha-ketoglutarate-dependent dioxygenase’; GDF8, growth differentiation factor 8 (also known as ‘myostatin’); IL-6,
interleukin 6; IL-15, interleukin 15; ITLN1, intelectin 1; PGC-1α, peroxisome proliferator-activated receptor-gamma
coactivator (PGC)-1alpha; PRDM16, PR domain containing 16; PYY, peptide YY; REN, renin; RETN, resistin.
Appendix B
Table A2. List of SNPs discarded for analyses because did not meet the Hardy–Weinberg equilibrium.
Gene SNP MA MAF
ACE2 rs2074192 T 42.6
ACE2 rs6632677 C 9.2
AGTR1 rs12721241 A 12.0
AGTR1 rs2675511 G 13.9
AGTR2 rs5193 T 15.9
AGTR2 rs12840631 G 18.1
AGTR2 rs6608590 T 41.6
BDKRB2 rs4900313 A 16.2
PGC1β rs17110586 G 14.8
PRC rs17114388 G 19.7
Abbreviations: see Table A1.
Table A3. List of SNPs discarded for analyses because the frequency of the minor allele was inferior
to 5%.
Gene SNP MA MAF
FGF21 rs838133 A 1.1
FGF21 rs838145 G 1.3
FNDC5 rs726344 A 0.2
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Table A3. Cont.
Gene SNP MA MAF
FST rs12152850 T 1.6
GDF-8 rs1805086 C 0.2
GDF-8 rs3791784 G 2.3
IL-6 rs1800795 C 0.7
IL-15 rs1589241 T 0.8
IL-6 rs1554606 T 1.8
ITLN1 rs11265509 T 4.7
Abbreviations: see Table A1.
Table A4. List of SNPs discarded for analyses because all individuals of the sample had the
same genotype.
Gene SNP Genotype
AGTR1 rs12721276 CC
PYY rs432747 GG
Abbreviations: see Table A1.
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